SNP Micro Array

  1. Home
  2. >
  3. Business
  4. >
  5. Research
  6. >
  7. SNP Micro Array

The Theragen PMRA chip is a microarray chip consisting of more than 820,000 reliable SNPs. Based on about 750,000 SNPs of an Asian PMRA chip from Thermo Fisher Co., it can identify the risk of general and rare diseases Asian people commonly develop. Also, by adding 50,000 customized SNPs strictly selected based on Theragen Etex’s 10 years of genetic analysis service know-how, it has been optimized for precision medicine, clinical trials, and cohort research for Korean people.
Health and beauty service based on Theragen PMRA chip
Various additional genetic test services are available at a low price with just one test application and blood collection.

Contact

Features and Advantages

Over 820,000 highly reliable markers
  • Accuracy 99.7%, Reproducibility 99.92%
  • Genome coverage MAF>5%: 94%, MAF>1%: 90%
As it was designed based on the Asian PMRA chip of Thermo Fisher Co., the accuracy of Theragen’s PMRA chip has the accuracy of the Asian PMRA chip.
Diversity of chip format (Minimum required sample : 23 cases)
As it has a chip with both 23-sample and 95-sample formats, a small amount of samples can be analyzed.
It is suitable for genetic test services and disease research.
It is possible to identify variations that have high clinical relevance such as immune disorders, mental disorders, cancer, rare diseases, and general diseases that Asian people develop.
Reasonable and affordable price
It is optimized for group research due to its reasonable and affordable price.
It is suitable for research on Asian races.
It includes 820,000 markers that are optimized for Asian people, especially Korean people.
Education support
When one hesitates to experiment due to a lack of GWAS analysis experience, education on research design, analysis methods and interpretation of analysis results is supported.

Chip use scope

  • Research on genetic variations related to various diseases (GWAS)
  • Genome information is secured by imputation (in silico fine mapping)
  • Provision of high genome coverage for research on exome and target sequencing
  • Research on reproducibility of reported GWAS variation
  • Research on genetic variations (nonsynonymous) that have a direct effect on protein formation in the genetic part related to reported diseases
  • Pharmacogenomics for the development of novel drugs
The global PMRA chip includes genes related to rare genetic diseases that are common in various races, immune reaction, pharmacogenomics research, and other important health issues. It is suitable for research on precision medicine for a wide range of races.

Features and Advantages

More than 900,000 highly reliable markers
  • Accuracy 99.8%, Reproducibility 99.95%
  • Genome coverage MAF>5% : 94%, MAF>1% : 90%
It is suitable for genetic test services and disease research.
It is possible to identify variations with high clinical relevance such as immune disorders, mental disorders, cancer, rare diseases, and general diseases.
It is suitable for research on all races.
It includes 900,000 markers for research on all races.

Chip use scope

  • Research on genetic variations related to various diseases (GWAS)
  • Genome information is secured by imputation (in silico fine mapping)
  • Provision of high genome coverage for research on exome and target sequencing
  • Research on reproducibility of reported GWAS variation
  • Research on genetic variations (nonsynonymous) that have a direct effect on protein formation in the genetic part related to reported diseases
  • Pharmacogenomics for the development of novel drugs.
While the existing SNP microarray chip is designed to be customized for Western people, the Korean chip is optimized for research on Koreans as it includes the risk of specific diseases that Korean people develop.

Features and Advantages

More than 830,000 highly reliable markers
  • Accuracy 99.5%, Reproducibility 99.5%
  • Genome coverage MAF>5% : 95%, MAF>1% : 74%

Chip use scope

  • Research on genetic variations related to various diseases (GWAS)
  • Genome information is secured by imputation (in silico fine mapping)
  • Provision of high genome coverage for research on exome and target sequencing
  • Research on reproducibility of reported GWAS variation
  • Research on genetic variations (nonsynonymous) that have a direct effect on protein formation in the genetic part related to reported diseases
  • Pharmacogenomics for the development of novel drugs. Composition of more than 830,000 markers. Retention of 96-array format.